Showing 5521-5540 of 7110 for: Cochrane Systematic Reviews Back
- Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Cochrane Systematic Reviews, 13-Mar-2012
Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia and inhibitory allo-antibodies and for prophylaxis and treatment of patients with congenital factor VII deficiency. It is also used for off-license indications to prevent bl
- Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome
Cochrane Systematic Reviews, 24-Aug-2015
Gonadotrophins are known to be effective in inducing ovulation in women with clomiphene-resistant polycystic ovary syndrome. Ovulation induction with FSH bears the risk of multiple follicle development and multiple pregnancies. The dose regimen used can a
- Recombinant growth hormone for children and adolescents with Turner syndrome
Cochrane Systematic Reviews, 5-Nov-2008
Turner syndrome (TS) affects about one in 1500 to 2500 live-born females. One of the most prevalent and salient features of the syndrome is extremely short stature. Untreated women are approximately 20 to 21 cm shorter than normal women within their respe
- Recombinant growth hormone for idiopathic short stature in children and adolescents
Cochrane Systematic Reviews, 5-Nov-2008
Idiopathic short stature (ISS) refers to children who are very short compared with their peers for unknown or hereditary reasons. Recombinant human growth hormone (GH) has been used to increase growth and final height in children with ISS.
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults
Cochrane Systematic Reviews, 23-Aug-2021
Cystic fibrosis (CF) is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas. People with CF often have malnutrition and growth delay. Adequate nutritional supplementation does not improve growth optimally and
- Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
Cochrane Systematic Reviews, 7-Oct-2021
Conventional treatment of X-linked hypophosphatemia with oral phosphate and calcitriol can heal rickets, but it does not always raise serum phosphate concentrations significantly, nor does it always normalize linear growth. Some clinical trials suggest th
- Recombinant human activated protein C for severe sepsis in neonates
Cochrane Systematic Reviews, 12-Mar-2012
Sepsis is a common problem in preterm and term infants. The incidence of neonatal sepsis has declined, but mortality remains high. Recombinant human activated protein C (rhAPC) possess a broad spectrum of activity modulating coagulation and inflammation.
- Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis
Cochrane Systematic Reviews, 24-Mar-2016
Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHuEPO use in predialysis patients
- Recombinant human growth hormone for treating burns and donor sites
Cochrane Systematic Reviews, 9-Sep-2014
Recombinant human growth hormone (rhGH) increases protein synthesis, therefore it is used in burns with a total body surface area (TBSA) greater than 40%, where there is frequently an increase in protein breakdown and a decrease in protein synthesis. This
- Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease
Cochrane Systematic Reviews, 16-Oct-2012
Recombinant human insulin-like growth factor I (rhIGF-I) is a possible disease modifying therapy for amyotrophic lateral sclerosis (ALS, which is also known as motor neuron disease (MND)).
- Recombinant human interleukin 10 for induction of remission in Crohn's disease
Cochrane Systematic Reviews, 30-Nov-2011
The etiology of Crohn’s disease remains unknown, nevertheless, it is apparent that inflammation is associated with an imbalance between proinflammatory and anti-inflammatory cytokines produced within the intestinal mucosa. Crohn’s disease represents a sta
- Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer
Cochrane Systematic Reviews, 5-Oct-2010
For patients with differentiated thyroid cancer (DTC) following thyroidectomy, thyroid hormone withdrawal (THW) for four to six weeks has been used for decades to increase serum thyroid-stimulating hormone (TSH) concentrations in order to enhance iodine-1
- Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
Cochrane Systematic Reviews, 27-Oct-2008
Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in
- Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles
Cochrane Systematic Reviews, 20-Sep-2010
During in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles, controlled ovarian hyperstimulation (COH) is performed with recombinant follicle stimulating hormone (rFSH) in combination with a gonadotrophin-releasing hormone
- Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles
Cochrane Systematic Reviews, 18-Jan-2011
Until recently, the main source of exogenous follicle stimulating hormone (FSH) for therapeutic use in infertility had been the urine of postmenopausal women. New developments have resulted in the production of FSH in vitro by recombinant DNA technology.
- Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles
Cochrane Systematic Reviews, 15-Nov-2012
Several systematic reviews compared recombinant gonadotrophin with urinary gonadotrophins (HMG, purified FSH, highly purified FSH) for ovarian hyperstimulation in IVF and ICSI cycles and these reported conflicting results. Each of these reviews used diffe
- Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles
Cochrane Systematic Reviews, 8-Mar-2011
For the last few decades urinary human chorionic gonadotrophin (hCG) has been used to induce final oocyte maturation triggering in in vitro fertilization (IVF) and intra-cytoplasmic sperm injection (ICSI) cycles. Recombinant technology has allowed the pro
- Recompression and adjunctive therapy for decompression illness
Cochrane Systematic Reviews, 16-May-2012
Decompression illness (DCI) is due to bubble formation in the blood or tissues following the breathing of compressed gas. Clinically, DCI may range from a trivial illness to loss of consciousness, death or paralysis. Recompression is the universally accep
- Reconstructive surgery for treating pressure ulcers
Cochrane Systematic Reviews, 13-Oct-2022
There are several possible interventions for managing pressure ulcers (sometimes referred to as pressure injuries), ranging from pressure-relieving measures, such as repositioning, to reconstructive surgery. The surgical approach is usually reserved for r
- Reconstructive Techniques After Rectal Resection for Rectal Cancer
Cochrane Systematic Reviews, 4-Aug-2008
Total mesorectal resection (TME) has led to improved survival and reduced local recurrence in patients with rectal cancer. Straight coloanal anastomosis after TME can lead to problems with frequent bowel movements, fecal urgency and incontinence. The colo
